Mizuho Reiterates Outperform Rating on Syndax Pharmaceuticals (SNDX)

Mizuho analyst Salim Syed reiterated an Outperform rating and $43.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst comments "Tonight post the close, Syndax reported 3Q26 earnings (press release, slides) and we caught up with management after the call. Overall a good quarter: Revuforj in-line; actual $60.7MM vs consensus $60.8MM (Vara), and QoQ growth remained in double-digit territory at 11%. Notably, tonight management provided for the first time r/r NPM1m patient transplant and post-transplant maintenance therapy rates, ~40% and ~50%, respectively, surprisingly high for this patient population (recall, NPM1m patients tend to be older, less likely to be fit for transplant). This could be a tailwind for longer-term NPM1m patient sales, as duration on Revuforj as post-transplant maintenance could potentially be longer than for patients that stayed on therapy but didn't go to transplant. There may be a slight temporary headwind to NPM1m sales as patients go off therapy for transplant and recovery, but longer term we see this as moderately positive."

For an analyst ratings summary and ratings history on Syndax Pharmaceuticals click here. For more ratings news on Syndax Pharmaceuticals click here.

Shares of Syndax Pharmaceuticals closed at $13.10 yesterday.

You May Also Be Interested In

• Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
• Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
• Avita Medical Ltd. (RCEL) PT Raised to $20 at TD Cowen